HOME >> BIOLOGY >> NEWS
Promising results in the battle against incurable ALS muscle disease

t the vascular endothelial growth factor (VEGF) plays a major role in this disease.

VEGF: a promising track to follow

VEGF is a signaling substance that controls the growth of blood vessels. To a large extent, a tissue in need of oxygen manufactures the protein, thereby developing new blood vessels so that the need for oxygen again diminishes. VEGF also helps neurons survive under stressful conditions. Last year, the work of Peter Carmeliet's team showed that persons who produce too little VEGF - due to certain variations in the gene that codes for VEGF - have a greater chance of developing ALS. Earlier this year, their research proved that gene therapy with the VEGF gene increased the life expectancy of ALS mice by 30%. But gene therapy is still a controversial method of treatment, whose path to the clinic can be quite long.

VEGF prolongs the life of ALS rats

So, investigation into a possible treatment using the VEGF protein has never been abandoned. Now, research from Erik Storkebaum and Diether Lambrechts, under Peter Carmeliet's direction, has shown the effectiveness of such a treatment on ALS rats. Testing the treatment on rats with a severe form of ALS and on rats with a milder form, the researchers found that, in both groups, the VEGF-treated rats contracted the disease later than the untreated animals, and they continued to live considerably longer.

The researchers also investigated what the optimal technique would be for administering VEGF. An ordinary injection proved to be ineffective. But continuous administration of the VEGF protein - by means of a small pump - directly into the cerebrospinal fluid (the fluid that circulates around the brain and the spinal cord) was quite effective.

New hope for patients

Furthermore, this technique permits a patient-oriented approach by enabling the administered dose of the VEGF protein to be easily controlled. Te
'"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
29-Nov-2004


Page: 1 2 3

Related biology news :

1. Promising protein may prevent eye damage in premature babies
2. Tailored treatments: Promising designer drug provides new insight into cancer biology
3. Promising antiobesity drug fails to produce clinically meaningful weight loss
4. Promising preclinical results with live attenuated H5N1 vaccines
5. Promising new research on hereditary diseases
6. Promising cell protein may play role in infection and dry eye
7. Promising anti-TB compound finally can be synthesized with ease
8. Promising new preventative treatment option for population of men at high risk of prostate cancer
9. Cooperative science program yields results
10. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
11. Smelling for first time results from knowing abnormalities in congenital loss of smell

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/28/2017)... Februar 2017  EyeLock LLC, ein marktführendes Unternehmen im ... biometrische Lösung zur Iris-Erkennung auf der neuesten ... auf dem Mobile World Congress 2017 (27. ... Halle 3, Stand 3E10, vorstellen. ... Haven™ – eine Kombination aus Hardware, Software ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... at a Marketing Roundtable on March 22 in Philadelphia. The event was offered ... , The Marketing Roundtable featured breakout groups and interaction with speakers ...
(Date:3/28/2017)... LONDON , March 28, 2017 ... to better understand Enzo Biochem and its partnering interests and ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ... and company data. The report will be delivered ...
(Date:3/28/2017)... , March 28, 2017  The National Pharmaceutical ... joined the health policy research organization as its newest ... and Regulatory Affairs ( North America ), ... of Directors. "We,re pleased to have Ipsen ... President Dan Leonard . "We welcome their insights ...
(Date:3/28/2017)... , March 28, 2017 Biostage, ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, today announced that Jim McGorry, CEO ... and BioEngineering panel at the MassBio 2017 ... 2:30 PM ET in Cambrige, Massachussetts. The 3D ...
Breaking Biology Technology:
Cached News: